Skip to main content
TipRanks
Go Ultimate75% OFF

OncoZenge AB (ONCOZ) AI Stock Analysis

0 Followers
SE:ONCOZ

OncoZenge AB

(Nasdaq OMX AB:ONCOZ)

Select Model
Rating:39Underperform
Price Target:SEK 3.00â–¼(-7.55% Downside)
Action:reiterated
Date:11/13/26

The score is driven primarily by substantial operating losses, declining revenue, and continued cash burn. Debt-free status offers limited financial support, but weak profitability, negative cash flow, unfavorable longer-term technical positioning, and a negative P/E ratio keep the overall score near the bottom of the range.

Positive Factors
Debt-Free Balance SheetThe current debt-free position and positive equity provide financial flexibility while the company develops its oncology products. Low leverage reduces interest burden and refinancing pressure, giving management more room to allocate capital toward commercialization and operational needs.
Negative Factors
Persistent Cash BurnMaterially negative operating and free cash flow show that the business is not yet funding itself from operations. Continued cash burn can require additional financing or a rapid improvement in revenue and costs, potentially limiting strategic flexibility over the coming quarters.

OncoZenge AB (ONCOZ) vs. iShares MSCI Sweden ETF (EWD)

-60%-40%-20%0%20%40%60%SE:ONCOZ-33.86%EWD+15.64%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
SEK 89.57M
Dividend Yield
―
Average Volume (3M)
67.71K
Price to Earnings (P/E)
-1.4
Beta (1Y)
1.45
Revenue Growth
115.26%
EPS Growth
-230.43%
Country
Sweden
Employees
1
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

OncoZenge AB Business Overview & Revenue Model

Company Description

OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinica...

OncoZenge AB Financial Statement Overview

Summary

Financial performance is weak overall: revenue declined 56.5%, EBIT and net margins were deeply negative, and operating cash flow remained substantially negative. Debt-free status and positive equity provide some support, but the underlying financial scores average below the minimum permitted component score.

Income Statement

15Very Negative

Balance Sheet

55Neutral

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue5.81M2.66M1,0003,00000
Gross Profit3.93M-4.84M1,0003,00000
EBITDA-21.96M-15.87M-8.69M7.27M2.77M-4.89M
Net Income-31.92M-15.94M-8.69M-15.90M-46.65M-3.89M
Balance Sheet
Total Assets33.80M15.34M11.43M20.34M36.89M85.23M
Cash, Cash Equivalents and Short-Term Investments24.30M3.71M3.86M12.63M29.14M51.22M
Total Debt07.50M0000
Total Liabilities15.12M15.92M1.48M1.70M2.92M4.90M
Stockholders Equity18.68M-587.00K9.95M18.64M33.97M80.32M
Cash Flow
Free Cash Flow-13.90M-13.06M-8.76M-17.08M-22.08M-10.12M
Operating Cash Flow-26.96M-13.06M-8.76M-17.08M-22.08M-4.77M
Investing Cash Flow000570.00K0-5.36M
Financing Cash Flow39.67M12.91M00051.34M

OncoZenge AB Technical Analysis

Technical Analysis SentimentNeutral
Last Price3.25

Price Trends

50DMA3.34Negative
100DMA4.31Negative
200DMA4.75Negative

Market Momentum

MACD-0.07Negative
RSI48.85Neutral
STOCH74.04Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ONCOZ, the sentiment is Neutral. The current price of 3.25 is above the 20-day moving average (MA) of 3.18, below the 50-day MA of 3.34, and below the 200-day MA of 4.75, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 48.85 is Neutral, neither overbought nor oversold. The STOCH value of 74.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ONCOZ.

OncoZenge AB Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

SE:ONCOZ against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
SE:CANTASE:CANTA61NeutralSEK 391.34M2.0463.09%―――
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
SE:ISOFOLSE:ISOFOL48NeutralSEK 326.26M-5.09-58.68%――35.02%
SE:ELICSE:ELIC45NeutralSEK 172.51M-7.31-56.09%――14.10%
SE:ONCOSE:ONCO44NeutralSEK 763.50M-2.81――65.37%43.28%
SE:IMMUSE:IMMU39UnderperformSEK 276.26M-2.43-19.14%――13.06%
SE:ONCOZSE:ONCOZ39UnderperformSEK 89.57M-1.38-970.69%―115.26%-230.43%

* Healthcare Sector Average

Performance Comparison

-50%0%50%100%SE:ONCOZSE:ONCOSE:ISOFOLSE:ELICSE:IMMUSE:CANTADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
SE:ONCOZ and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
SE:ONCOZOncoZenge AB3.25-1.68-34.07%
SE:ONCOOncopeptides AB1.77-3.13-63.86%
SE:ISOFOLIsofol Medical AB1.020.3245.85%
SE:ELICElicera Therapeutics AB2.58-2.68-50.86%
SE:IMMUImmunicum AB4.36-1.30-23.06%
SE:CANTACantargia AB1.39-2.06-59.77%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026